Back to Search
Start Over
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1Rvariant protective for coronary heart disease
- Source :
- Science Translational Medicine; June 2016, Vol. 8 Issue: 341 p341ra76-341ra76, 1p
- Publication Year :
- 2016
-
Abstract
- A missense variant in GLP1R associated with lower fasting glucose levels and protective against T2D is associated with lower risk of coronary heart disease, suggesting that GLP1R agonists are not associated with an unacceptable increase in cardiovascular risk.
Details
- Language :
- English
- ISSN :
- 19466234 and 19466242
- Volume :
- 8
- Issue :
- 341
- Database :
- Supplemental Index
- Journal :
- Science Translational Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs39300172
- Full Text :
- https://doi.org/10.1126/scitranslmed.aad3744